Safety of parathyroid hormone for the treatment of osteoporosis.
Teriparatide (recombinant human 1-34 parathyroid hormone) has been registered for the treatment of postmenopausal osteoporosis and osteoporosis in men for more than 5 years, whereas 1-84 parathyroid hormone has just recently been registered in Europe for osteoporosis management. Therefore, more data are available regarding the long-term safety of teriparatide. The issues to be considered are the effects of the registered dose of teriparatide (20 microg/day) on the incidence of hypercalcemia, hypercalciuria, and hyperuricemia, and the US Food and Drug Administration's "black-box" warning regarding osteogenic sarcoma in the rat model. This review discusses these issues and provides the author's extensive clinical experience and advice on the use of teriparatide in clinical practice.
Miller
Paul D
PD
Colorado Center for Bone Research, 3190 South Wadsworth Boulevard, Suite #250, Lakewood, CO 80227, USA. millerccbr@aol.com
D000818:Animals; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000139:chemically induced; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D012516:Osteosarcoma / Q000139:chemically induced; D010281:Parathyroid Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D051381:Rats; D011916:Rats, Inbred F344; D019379:Teriparatide / Q000009:adverse effects* / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D019379:Teriparatide